Table 5.

Clinical outcomes after rituximab and intravenous immunoglobulin therapy.

Regimen	CR, n (%)	PR, n (%)	Relapse, n (%)	Infection, n (%)
CIST→RTX→IVIg* N=2	1 (50%)	1 (50%)	None	None
CIST→RTX+IVIg N=2	1 (50%)	1 (50%)	None	1 (50%)
CIST→IVIg→RTX N=8	4 (57.1%) *	3 (42.9%) *	4 (50%)	2 (25%)

*One patient did not report the final outcome as CR or PR, but only clinical improvement.

Hence, the number of patients in Table 3 is 11.

CIST, conventional immunosuppressive therapy; RTX, rituximab; IVIg, intravenous immunoglobulin; CR, complete response; PR, partial response.